Table 2.

Key disease-modifying agents currently available for MS in the EU

Oral agents	Indication [administration]
Cladribine	Highly active relapsing MS [2 short courses 1 year apart]
Fingolimod	Highly active relapsing-remitting MS [daily]
Teriflunomide	Relapsing-remitting MS [daily]
Dimethyl fumarate	Relapsing-remitting MS [twice daily]

Parenteral agents	Indication [administration]
Interferon-β1a,1b	Relapsing-remitting MS, relapsing MS, active secondary progressive MS [every 2 days or thrice per week SC or once per week IM]
Peg-interferon-β1a	Relapsing-remitting MS [once every 2 weeks SC]
Glatiramer acetate	Relapsing-remitting MS [daily or thrice per week SC]
Alemtuzumab	Active relapsing-remitting MS [2 short IV courses 1 year apart; ≤ 2 more if needed]
Natalizumab	Highly active relapsing-remitting MS [once every 4 weeks IV]
Ocrelizumab	Active relapsing MS or early primary progressive MS [2 IVs 2 weeks apart, then 1 IV once every 6 months]

IM intramuscular, IV(s) intravenous infusion(s), MS multiple sclerosis